Form 10-Q · Quarterly report
ResMed| 10-Q, filed Oct 30, 2026
- Filed
- CIK
- 0000943819
- Accession no.
- 0000943819-26-000089
Summary
ResMed reported first-quarter fiscal 2027 net revenue of $1.4 billion, up 6% year over year, with gross margin of 61.5% and diluted EPS of $2.92 versus $2.37 a year earlier. It completed the sale of its MatrixCare business on September 1, 2026 as part of a portfolio optimization strategy.
Key points
- Net revenue rose to $1.415 billion from $1.336 billion; Sleep and Breathing Health revenue rose 8% to $1.260 billion, while Residential Care Software revenue fell 7% to $155 million.
- Gross margin was 61.5%, up from 61.2%; diluted EPS was $2.92, up from $2.37.
- Research and development investment was $103 million, or 7.3% of net revenues.
- ResMed completed the previously announced sale of its MatrixCare business on September 1, 2026; MatrixCare results through disposition are included in continuing operations and the Residential Care Software segment.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management's Discussion Overview The following is an overview of our results of operations for the three months ended September 30, 2026. Management’s discussion and analysis of financial condition and results of operations, or the MD&A, is intended to help the reader understand our results of operations and financial condition. It is provided as a supplement to, and should be read in conjunction with, the condensed consolidated financial statements and notes included in this report. We are a global leader in digital health and cloud-connected medical devices. We design innovative technology with the intention to empower people to live happier, healthier lives. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.